Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Siscapa Assay Technologies, Inc.. (3/10/14). "Press Release: Selena Larkin Appointed VP Marketing and Sales for Siscapa Assay Technologies". Washington, DC.

Organisation Organisation Siscapa Assay Technologies Inc. (SAT)
Products Product SISCAPA® assay (Stable Isotope Standards and Capture by Anti-Peptide Antibodies)
  Product 2 mass spectrometry (MS)
Persons Person Larkin, Selena (Siscapa 201403– VP Marketing + Sales before Agilent + Biocius + AB Sciex)
  Person 2 Anderson, N. Leigh (Plasma Proteome Institute 200808 + SCISCAPA Assay Technologies)

SISCAPA Assay Technologies, Inc. (SAT), developer of precision mass spectrometry assays for quantitation of proteins, announces the addition of Selena Larkin to its leadership team.

Selena joins SAT as Vice President of Marketing and Sales and will be responsible for commercialization of SISCAPA® technology, including custom reagent development and CRO services. Selena's appointment will support the company's growing list of customers in clinical diagnostics and its continued global expansion into the academic and pharmaceutical research market.

"SAT is very happy to welcome Selena to the SISCAPA team", said Leigh Anderson, SAT's CEO. "Her experience in promotion of innovative technologies, her understanding and enthusiasm for SISCAPA, and her broad global network across the life science mass spectrometry space will help further speed our company growth and market adoption of SAT's high-specificity, multiplexable mass spectrometry-based assay products and services."

Selena most recently served as Global Director of Pharmaceutical Strategy at Agilent Technologies, where she drove multinational collaborations to position Agilent as a preferred strategic partner. She joined Agilent through acquisition of BIOCIUS Life Sciences, where she was a founder, having been responsible for commercialization of RapidFire technology for high-throughput mass spec sample preparation. Prior positions include representation of capital equipment, reagents, software and CRO services (Applied Biosystems/Sciex) and cell culture reagents (Irvine Scientific).

"I am very excited to join this growing organization and drive continued market development for a truly enabling technology", Selena said. "It has been a pleasure for me to observe the evolution and steady market uptake of SISCAPA from use in targeted proteomics and biomarker verification to now being a recognized tool for clinical diagnostics and basic research".

"I am particularly looking forward to applying my prior experience in commercialization at a growth-stage company. SAT has proven technology, exceptional people and a loyal customer base. I am in a privileged position to build upon our marketing message and build a strong global sales channel."

Selena holds a Ph.D. in Medicine (protein chemistry) from the University of Melbourne, Australia and an M.B.A. in International Business from the University of Maryland.

About SISCAPA Assay Technologies, Inc.

SISCAPA Assay Technologies Inc. (SAT) delivers high-sensitivity, high-throughput specific assays for proteins including clinical biomarkers using SISCAPA® affinity-MS technology. Additional information about SISCAPA technology, reagents and business opportunities is available at

For more information contact Leigh Anderson at (301) 728-1451

Record changed: 2016-03-19


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Siscapa Assay Technologies Inc. (SAT)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture [LSUS] – The Business Web Portal 600x60px

» top